All articles by Vemula Pravalika
Vemula Pravalika
Thermo Fisher Scientific and Project HOPE Partner to Advance Health Equity Among HIV Positive Youth in Sub-Saharan Africa
Collaboration designed to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink
Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on December 14, 2023
Medical Device First to Enter the European Market with Sustainable, Innovative Sterilization Approach with Chlorine Dioxide Gas
The first ever CE mark was awarded to a medical device sterilized using chlorine dioxide gas following new MDR regulations. Sterilization services are performed by ClorDiSys Solutions, Inc in their New Jersey, FDA registered contract sterilization facility. The device is a Class II medical device that is a surgical lighting device to provide illumination of an electrocautery pencil during surgery. The device contains an embedded battery, forcing restrictions on the sterilization modality. Ethylene oxide is becoming a growing concern for the medical device industry due to its environmental and health concerns and limited sterilization capacity. However, it is also explosive, meaning the embedded battery was not compatible. Material compatibility and overall efficacy eliminated contending methods such as Gamma irradiation, dry heat, vaporized hydrogen peroxide, E-Beam, and other methodologies. This left chlorine dioxide as the clear sterilization approach due to the materials and inclusion of an embedded battery within the device.
Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.
Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCID
Innovative, easy-to-use molecular diagnostics workflow reduces complexity and costs for labs
looking to expand newborn screening capabilities
Certest completes the expansion of its new facilities
The construction of the two new buildings has represented an investment of 22 million euros
Bracco Announces Long-Term Strategic Partnership with ulrich medical for Syringeless Magnetic Resonance Injectors
The private label arrangement will bring a new syringeless magnetic resonance (MR) injector to the U.S. 510(k) premarket notification has been submitted to the U.S. Food and Drug Administration
Octapharma to present new clinical and scientific data at ASH 2023 from ongoing research initiatives aimed at advancing care for people living with bleeding disorders
New clinical data from Octapharma’s haematology portfolio will be presented during the scientific program at the 65th American Society of Hematology (ASH) Meeting and Exposition, which is being held on December 9–12, 2023, in San Diego, California. New data from the prospective clinical trial using wilate® for prophylaxis in patients with von Willebrand disease (VWD) will be presented. Furthermore, the design of a new phase IV clinical trial of bone and joint health in people with haemophilia A will be presented, in addition to updates from research collaborations between Octapharma and academic institutions.
Attend the Healthcare Innovation Summit Africa 2023
As technology continues to transform and disrupt every sector, the health sector is no exception. Digital innovation is having a tremendous impact on the healthcare industry from the way individuals gain access to services, to the breakthrough development of new technology that is radically transforming diagnostic procedures.
deepc Establishes MONAI Compatibility, Strengthening Its Commitment to Open-Source Collaboration and Global Healthcare Transformation
deepc, a leading MedTech company, aligns strategically with MONAI, the Medical Open Network for Artificial Intelligence. A community-driven open-source framework co-founded by NVIDIA and King’s College London, MONAI aims to advance healthcare through medical imaging. By ensuring MONAI compatibility on its platform, deepcOS, deepc emphasizes commitment to open-source AI, interoperability, and global AI development standards.